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5-month-old 5xFAD mice compared with 2.5-month-old 
5xFAD mice, MRI T1 relaxation time did not change.
Conclusions In summary, our data suggest that MRI T1 
relaxation time is neither a sensitive measure of disease 
onset nor progression at early stages in the 5xFAD mouse 
transgenic mouse model.
Keywords Alzheimer’s disease · Transgenic mice · 
Magnetic resonance imaging · Alzheimer beta-protein · 
Inflammation
Abbreviations
5xFAD  Five familial Alzheimer’s disease mutations
Aβ  Amyloid-β
AD  Alzheimer’s disease
FOV  Field of view
GFAP  Glial fibrillary acidic protein
Iba-1  Ionized calcium binding adaptor molecule 1
PET  Positron emission tomography
Mo  Month
MRI  Magnetic resonance imaging
ROI  Region of interest
TE  Echo time
TR  Repetition time
WT  Wild-type
Introduction
Alzheimer’s disease (AD) is clinically characterised by 
the increasing decline of cognitive functions that eventu-
ally leaves the patient dependent on custodial care. Stud-
ies in sporadic and autosomal dominant AD support a 
sequence of pathological changes, namely increased brain 
amyloidosis, tau pathology, decreased glucose metabolism, 
Abstract 
Objectives In the present study, we have tested whether 
MRI T1 relaxation time is a sensitive marker to detect early 
stages of amyloidosis and gliosis in the young 5xFAD 
transgenic mouse, a well-established animal model for Alz-
heimer’s disease.
Materials and methods 5xFAD and wild-type mice were 
imaged in a 4.7 T Varian horizontal bore MRI system to 
generate T1 quantitative maps using the spin-echo multi-
slice sequence. Following immunostaining for glial fibril-
lary acidic protein, Iba-1, and amyloid-β, T1 and area frac-
tion of staining were quantified in the posterior parietal and 
primary somatosensory cortex and corpus callosum.
Results In comparison with age-matched wild-type mice, 
we observed first signs of amyloidosis in 2.5-month-old 
5xFAD mice, and development of gliosis in 5-month-
old 5xFAD mice. In contrast, MRI T1 relaxation times of 
young, i.e., 2.5- and 5-month-old, 5xFAD mice were not 
significantly different to those of age-matched wild-type 
controls. Furthermore, although disease progression was 
detectable by increased amyloid-β load in the brain of 
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neurodegeneration, and brain atrophy—with amyloidosis 
being the earliest component, starting years or even dec-
ades before clinical symptoms, i.e., cognitive decline, begin 
to show [1–3]. In addition, there is now good evidence for 
neuroinflammation in the brain of AD patients [4, 5]. Acti-
vated microglia and astrocytes appear to play key roles in 
regulating AD pathogenesis, while they can have both pro-
tective and detrimental effects [6–15].
Current diagnostic criteria used to identify AD in people 
with dementia rely on advanced neurological impairment—
which is irreversible with current treatment options. To 
date, diagnostic markers that are sensitive to early disease 
stages are not available. Early biomarkers of AD can aid 
presymptomatic diagnosis, drug development by provid-
ing surrogate endpoints, treatment decisions, and disease 
monitoring [16]. Neuroimaging techniques using positron 
emission tomography (PET) exist to measure changes in 
glucose metabolism, currently the most common diagnostic 
criterion for AD [17], and also amyloid-β (Aβ) deposition, 
tau aggregation, and neuroinflammation. Magnetic reso-
nance imaging (MRI) is also recognised as an important 
tool in AD diagnosis and has some advantages over PET in 
that it is cheaper and currently more widely available. MRI 
enables visualisation of the medial temporal lobe, in which 
atrophy is related to AD and its severity [18, 19]. Although 
MRI is already routinely used to monitor disease progres-
sion at late stages of AD, i.e., after the onset of cognitive 
decline, it remains unclear whether this technique can also 
be applied to identify early changes in the brain of AD 
patients before clinical symptoms become apparent.
In a cross-sectional analysis of 21 subjects with AD and 
32 similarly aged healthy controls, AD was characterised 
by reduced quantitative T1 and T2 values [20]. In previous 
work by the same authors, decreased T1 values were found 
in patients with dementia with Lewy bodies compared with 
control subjects, highlighting the potential of T1 measures 
in general to detect changes caused by neurodegeneration 
[21]. Using 5xFAD transgenic mice, a well-recognised AD 
mouse model [22–24], we have previously shown that at 
the age of 11 months, 5xFAD mice have reduced MRI T1 
relaxation times in the lower layers of the posterior pari-
etal and primary somatosensory areas of the cortex and the 
corpus callosum compared with age-matched wild-type 
controls [25]. The cortex has a complex architecture that is 
made up of several layers, each defined by varying densi-
ties of myelin, neuronal cells, and receptors [26]. Aβ depo-
sition also follows a layered pattern in the cortex [25, 27]; 
regional variations of tissue changes related to Aβ deposi-
tion, gliosis, and/or neuronal loss may not be captured in 
large regions of interest that include less affected areas of 
tissue. We previously found in the cortex of 11-month-old 
5xFAD mice a pattern of T1 reductions that broadly cor-
respond to the pattern of Aβ reduction [25]. This indicates 
that quantitative MRI can provide information about tissue 
changes in specific regions of the mouse brain provided 
regions of interest (ROI) are placed appropriately. Due 
to the higher spatial resolution allowed by quantitative-
T1 MRI than diffusion tensor imaging and magnetisation 
transfer ratio MRI, quantitative T1 measurements have 
better chance of detecting changes in small regions of 
the brain. Here, we have extended these studies on young 
5xFAD mice to test whether the determination of MRI 
T1 relaxation times is a sensitive method capable of iden-
tifying early changes in the AD mouse brain, such as the 
beginning of amyloidosis and gliosis.
Materials and methods
Transgenic mice
This study was carried out in strict accordance with the UK 
Home Office Animals Scientific Procedures Act 1986. The 
protocol was approved by the committee of the UK Home 
Office (PPL number: 70/7075). All efforts were made to 
minimise suffering. Mice were purchased from Jackson 
Laboratory (5xFAD strain name: B6SJL-Tg[APPSwFlLon, 
PSEN1*M146L*L286 V]6799Vas/Mmjax]; stock number: 
006554; and non-carrying [wild-type] mice strain name: 
B6SJF1/J; stock number: 100012). A colony of transgenic 
and wild-type controls was produced by crossing hemizy-
gous 5xFAD mice with wild-type mice. Mice were geno-
typed using polymerase chain reaction and gel electropho-
resis. Eleven young mice [five wild-type and six 5xFAD 
(mean age = 2.6 months, SD = 0.16)] and ten older mice 
[five wild-type and five 5xFAD (mean age = 5.2 months, 
SD = 0.21)] were imaged. For simplicity, we describe 
these ages as 2.5 and 5 months throughout this report. A 
mixture of males and females were used in all groups. 
To compare Aβ load in young 5xFAD mice with that of 
old mice, we additionally quantified Aβ load in stained 
sections from 11-month-old mice that were previously 
obtained using the same methods of animal breeding and 
immunohistochemistry.
In vivo MRI
In vivo MR images were acquired on a 4.7 T Varian hori-
zontal bore MRI system with a mouse brain coil setup 
comprising a volume transmit coil and surface coil receiver 
(RAPID Biomedical GmBH, Würzburg-Rimpar, Ger-
many). Mice were initially anaesthetised with isoflurane, 
consisting of an O2 mixture (2 L/min), administered in a 
sealed tank fitted to an isoflurane scavenger system. Sub-
sequently, a 1:2:1 mixture of Hypnorm (0.315 μg/mL fen-
tanyl citrate and 10 mg/mL fluanisone), sterile water, and 
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Hypnovel (5 mg/mL midazolam) was administered intra-
peritoneally at 10 mg/kg bodyweight. Body temperature 
was maintained by a warming bed integrated into the imag-
ing coil apparatus.
For each mouse, five images were acquired using the 
spin echo multi-slice sequence with repetition times (TR) 
of 250, 500, 1000, 2000, 4000 ms and 16, 8, 4, 2, 2 aver-
ages, respectively, to maintain a similar signal-to-noise 
ratio for each TR. Other imaging parameters remained 
constant for all images: echo time (TE) = 14 ms; field of 
view = 30 × 30 mm; matrix = 128 × 128; nine contiguous 
slices of 1 mm thickness with the most anterior of the nine 
slices positioned just behind the olfactory bulb; total acqui-
sition time = 51.2 min. The range of TRs used was cho-
sen to adequately quantify the range of T1 relaxation times 
in the mouse brain. Immediately after imaging, the mouse 
was culled using the Schedule 1 method (dislocation of the 
neck) and the brain was placed in formalin with the skull 
left intact to retain the shape of the brain. All brain samples 
were soaked in formalin for 5 days before being processed 
for immunohistochemistry.
Immunohistochemistry
Fixed brains were removed from the skull and sliced into 
1 mm thick coronal sections using a matrix to match the 
imaging slices taken during MRI. Serial sections taken 
from the 1 mm mouse brain slices were stained for glial 
fibrillary acidic protein (GFAP) [Novocastra mouse 
monoclonal clone GA5 supplied by Leica Microsystems, 
Newcastle-upon-Tyne, UK (product code: NCL-GFAP-
GA5)], ionized calcium binding adaptor molecule 1 (Iba-
1) [MenaPath rabbit Polyclonal antibody supplied by A. 
Menarini Diagnostics, Wokingham, UK (product code: 
MP-290-CR05)], and Aβ [Novocastra mouse monoclonal 
Aβ clone 6F/3D supplied by Leica Microsystems, New-
castle-upon-Tyne, UK (product code: NCL-B-Amyloid)]. 
For GFAP and Iba-1 staining, antigen retrieval was car-
ried out using Epitope Retrieval Solution, pH 6 at 100 °C 
for 30 min; GFAP antibody was applied for 15 min at 
a dilution of 1:200 and Iba-1 antibody was applied for 
15 min at a dilution of 1:800. For Aβ staining, sections 
were treated with Epitope Retrieval Solution, pH 9 at 
100 °C for 30 min and 90% (v/v) formic acid for 5 min; 
Aβ antibody was applied for 15 min at a dilution of 1:50. 
Immunohistochemical staining was carried out using 
Bond III fully automated staining system with their Bond 
Polymer Refine detection system and associated reagents, 
supplied by Leica Microsystems, Newcastle-upon-Tyne, 
UK. This automated system provides high sensitivity and 
reproducibility in immunohistochemical staining. Digital 
images of the histological slides were captured using a 
Nikon Super Coolscan 8000 ED camera, at 100% scale 
and 4000 pixels/in, and using the same settings for all 
images.
Quantification of T1 relaxation times and 
immunohistochemical marker area fraction
ImageJ software (Rasband, W.S., ImageJ, US National 
Institutes of Health, Bethesda, MD, USA, http://imagej.nih.
gov/ij/, 1997–2012) [28] was used to generate T1 quantita-
tive maps. For each dataset, MR images at each TR were 
normalised by dividing by the number of averages in its 
acquisition using the ImageJ maths function, and images 
were stacked and co-registered using the plugin, Stackreg 
(Thevenaz et al., Lausanne, Switzerland, 1998) [29]. T1 
quantitative maps were generated from the stacked images 
using the MRI Analysis Calculator ImageJ plugin (https://
imagej.nih.gov/ij/plugins/mri-analysis.html) by Karl 
Schmidt. Mean T1 relaxation times were recorded for areas 
that covered the lower cortex and corpus callosum. This 
was done for the lower cortex by placing three small ROIs 
(4 pixels × 4 pixels) each in the left and right hemispheres 
that covered the lower layers of the posterior parietal and 
primary somatosensory areas of the cortex (a region we call 
lower cortex). For the corpus callosum, two ROIs (5 pix-
els × 2 pixels) were placed directly below the ROIs placed 
in the lower cortex and over the dark area corresponding to 
dense myelin areas of the corpus callosum. The use of mul-
tiple ROIs, as opposed to one hand drawn selection, was 
chosen so to cover a large enough area whilst keeping the 
area and placement of ROIs consistent between all mice.
ImageJ was used to calculate the area fraction of posi-
tive staining (percentage pixels in the ROI that have been 
highlighted using the threshold function). The method for 
calculating area fraction was followed as described in the 
online ImageJ documentation, http://rsbweb.nih.gov/ij/
docs/examples/stained-sections/index.html. Red–green–
blue images were converted to 8-bit, grey scale images; a 
set threshold level was chosen for each of the three immu-
nological stains that selected the areas of positive staining 
but did not include other areas (upper and lower threshold 
values: Aβ = 0–180; GFAP = 0–210; Iba-1 = 0–220). 
ROIs in the MR images were transferred to approximately 
the same anatomical regions in the histological images and 
increased in size by a factor of 12, equal to the difference 
in scale factor of the MR and histological images, and area 
fraction was calculated automatically.
Statistics
All data are presented as mean ± SEM. Statistical sig-
nificance of differences between experimental groups was 
evaluated using the SPSS software [IBM Corp. Released 
2013. IBM SPSS Statistics for Windows, Version 22.0. 
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Armonk, NY, USA: IBM Corp (http://www.IBM.com)]. 
Following a one-way analysis of variance (ANOVA) in a 
2 × 2 factorial design, means were compared using Fish-
er’s unprotected least significant difference test. An addi-
tional analysis was made on the 5xFAD mice to compare 
the lower cortex with corpus callosum for each of the his-
tological markers Aβ, GFAP, and Iba-1 using a paired t test. 
Data were considered to be statistically significant with 
p < 0.05. To compare Aβ load in young 5xFAD mice with 
that of old mice, one-way ANOVA was used to determine 
whether any differences between group means, i.e., Aβ 
load in the lower cortex and corpus callosum of 2.5-, 5-, 
and 11-month-old mice, were statistically significant.
Results
Quantification of Aβ load and gliosis in young 5xFAD 
mice
To understand whether the quantified T1 relaxation time 
can be used to detect early changes in the brain of young 
5xFAD mice, immunohistochemistry was first applied in 
order to determine time points of Aβ plaque development 
and accompanied neuroinflammation. Although it has been 
reported previously that Aβ deposition and gliosis begin in 
some brain regions of 5xFAD mice at the age of 2 months 
and increase steadily afterwards [22], to date no quantita-
tive data are available characterising Aβ load and neuroin-
flammation (1) in different brain regions and (2) at differ-
ent ages of 5xFAD mice. To determine early changes in the 
brain of 5xFAD mice, we quantified Aβ deposition, astro-
cytosis and microgliosis in brains of 2.5- and 5-month-old 
5xFAD mice and age-matched wild-type mice. Aβ staining 
(to determine Aβ plaque development), GFAP staining (to 
quantify activated astrocytes) and Iba-1 staining (to quan-
tify activated microglial cells) were analysed in two brain 
regions, namely the lower cortex and the corpus callosum. 
We focussed specifically on these two brain regions, as they 
have been identified as areas with the largest differences in 
MRI T1 relaxation time upon comparison of 11-month-old 
wild-type and 5xFAD mice [23].
Quantification of astrocytosis and microgliosis in young 
5xFAD mice
First, we quantified area fraction of GFAP staining in lower 
cortex and corpus callosum of 2.5- and 5-month-old wild-
type and 5xFAD mice. There was a statistically significant 
difference between groups in the lower cortex (p < 0.05) 
and the corpus callosum (p < 0.05) as determined by one-
way ANOVA. The Fisher’s unprotected least significant dif-
ference test was used to show which groups differed from 
each other. As demonstrated in Fig. 1, in both brain regions, 
GFAP staining was not significantly different between 
wild-type and 5xFAD mice at the age of 2.5 months 
(p = 0.324 for lower cortex; p = 0.343 for corpus callo-
sum; WT n = 5, 5xFAD n = 6). However, at the age of 
5 months, significant differences were found in the area 
fraction of GFAP staining between wild-type and 5xFAD 
mice for both regions. In comparison with wild-type mice, 
in 5xFAD mice, GFAP area fraction was 16-fold larger 
(a)
(b)
(c)
Fig. 1  GFAP staining in wild-type (WT) and 5xFAD mice. a An 
example of a glial fibrillary acidic protein (GFAP) stained section 
from a 5-month-old ( 5 mo) 5xFAD mouse. Charts show area fraction 
(%) (mean ± SEM) in the lower cortex (b) and corpus callosum (c) in 
2.5-month-old (2.5 mo) and 5 mo WT and 5xFAD mice. Regions of 
interest are shown by red ellipses. n.s. not significant; **p < 0.01
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(p < 0.01; WT n = 5, 5xFAD n = 5) in the lower cortex, 
and fourfold larger (p < 0.01; WT n = 5, 5xFAD n = 5) 
in the corpus callosum. Furthermore, GFAP area fraction 
was significantly larger in corpus callosum than in the 
lower cortex of both 2.5- and 5-month-old mice (p < 0.05 
in both cases). In comparison with 2.5-month-old 5xFAD 
mice, GFAP area fraction of 5-month-old 5xFAD mice 
was threefold increased (p < 0.05) in the lower cortex, but 
only numerically higher in the corpus callosum [twofold 
increased (p = 0.083)].
Furthermore, analyses of Iba-1 staining were performed 
to study microgliosis in young 5xFAD mice. Figure 2 
shows an example of a brain slice stained with Iba-1 and 
summarises results of Iba-1 staining in the lower cortex 
and corpus callosum in wild-type and 5xFAD mice at the 
age of 2.5 and 5 months. Qualitatively, Iba-1 staining was 
similar to that obtained for GFAP staining. There was a 
statistically significant difference between groups in the 
lower cortex (p < 0.01) and the corpus callosum (p < 0.01) 
as determined by one-way ANOVA. Analysis of the lower 
cortex and of the corpus callosum did not reveal any signif-
icant differences in area fraction of Iba-1 staining between 
2.5-month-old wild-type and 5xFAD mice (p = 0.972 for 
lower cortex; p = 0.600 for corpus callosum; WT n = 3, 
5xFAD n = 6). In contrast, Iba-1 staining was much more 
pronounced in 5-month-old 5xFAD mice compared with 
5-month-old wild-type mice. In 5-month-old 5xFAD mice, 
area fraction of Iba-1 staining was 12-fold higher in the 
lower cortex (p < 0.01; WT n = 5, 5xFAD n = 5) and six-
fold higher in the corpus callosum (p < 0.01; WT n = 5, 
5xFAD n = 5) in comparison with the corresponding brain 
areas of wild-type mice. No differences were found in Iba-1 
area fraction between lower cortex and corpus callosum of 
either 2.5- or 5-month-old 5xFAD mice (p = 0.077 and 
p = 0.334, respectively). Iba-1 area fraction in the lower 
cortex (fourfold; p < 0.01) and corpus callosum (sixfold; 
p < 0.01) increased significantly in 5-month-old 5xFAD 
mice compared with 2.5-month-old 5xFAD mice.
Quantification of Aβ load in young 5xFAD mice
Analysis with one-way ANOVA found statistically sig-
nificant differences between groups in the lower cortex 
(p < 0.001) and corpus callosum (p < 0.001). No significant 
Aβ staining was detectable in the brain of wild-type mice 
of both age groups. However, in agreement with Oakley 
et al. [22], Aβ staining was visible in 5xFAD mice as young 
as 2.5-months-old. Staining was more pronounced in the 
lower cortex than in the corpus callosum. In 2.5-month-
old 5xFAD mice, Aβ area fraction in the lower cortex was 
96-fold higher (p < 0.05) than in the corpus callosum. Sim-
ilar to observations made for 2.5-month-old mouse brains, 
higher amounts of Aβ were detected in the lower cortex 
than in the corpus callosum of 5-month-old 5xFAD mice 
(Fig. 3). In comparison with 5-month-old WT mice, in 
5-month-old 5xFAD mice, Aβ deposition was substantially 
enhanced in both brain regions investigated (lower cortex: 
p < 0.001; corpus callosum: p < 0.001; WT n = 5, 5xFAD 
n = 5) (Fig. 3). Furthermore, compared with 2.5-month-old 
5xFAD mice, Aβ area fraction was significantly increased 
in the lower cortex (threefold; p < 0.001) and corpus cal-
losum (111-fold; p < 0.001) of 5-month-old 5xFAD mice.
(a)
(c)
(b)
Fig. 2  Iba-1 staining in wild-type (WT) and 5xFAD mice. a An 
example of a brain slice from a 5-month-old (5 mo) 5xFAD mouse 
stained with ionized calcium binding adaptor molecule 1 (Iba-1). 
Charts show area fraction (%) (mean ± SEM) in the lower cortex (b) 
and corpus callosum (c) in 2.5-month-old (2.5 mo) and 5 mo WT and 
5xFAD mice. Regions of interest are shown by red ellipses. n.s. not 
significant; **p < 0.01
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Quantification of Aβ load in old 5xFAD mice
Substantial Aβ plaque load has previously been reported 
for both brain regions, the lower cortex and corpus callo-
sum, in old 5xFAD mice [22, 25]. To compare Aβ load in 
lower cortex and corpus callosum of young 5xFAD mice 
with that of old mice, we additionally quantified Aβ area 
fraction in brain slices obtained from 11-month-old mice 
using the method described above. Analysis with one-way 
ANOVA found statistically significant differences between 
groups in the lower cortex (p < 0.001) and corpus callo-
sum (p < 0.001). In the lower cortex, Aβ area fraction of 
11-month-old 5xFAD mice was 70-fold (p < 0.001; 2.5 mo 
n = 5, 11 mo n = 6) higher than that of 2.5-month-old 
mice and 23-fold (p < 0.001) higher than that of 5-month-
old 5xFAD mice. Similarly, in the corpus callosum, a much 
higher Aβ load was found for 11-month-old mice compared 
with young mice. Aβ area fraction in the corpus callosum 
of 11-month-old 5xFAD mice was 4090-fold (p < 0.001; 
2.5 mo n = 6, 11 mo n = 6) and 37-fold (p < 0.001; 5 mo 
n = 5, 11 mo n = 6) increased when compared with that 
of 5xFAD mice at the age of 2.5 months and 5 months, 
respectively.
MRI T1 signals of young 5xFAD mice
We have previously reported that 11-month-old 5xFAD 
mice are characterised by significantly lower MRI T1 relax-
ation time compared to age-matched wild-type mice, while 
differences were most pronounced in the lower cortex and 
the corpus callosum (white matter) [25]. To test whether 
MRI T1 can be used to detect early changes in Aβ load and 
neuroinflammation in AD mice, we determined MRI T1 
relaxation time in young wild-type and 5xFAD mice. No 
statistical significant differences in T1 relaxation time were 
found between the groups (2.5- and 5-month-old mice) as 
determined by one-way ANOVA, indicating that T1 relaxa-
tion times in the lower cortex as well as in the corpus callo-
sum differed neither between wild-type and 5xFAD mice at 
both age groups nor between 2.5- and 5-month-old 5xFAD 
mice (Fig. 4).
Discussion
Histochemistry of young 5xFAD mice
In this study, we present the first quantification of amyloi-
dosis, astrocytosis, and microgliosis in the lower cortex and 
the corpus callosum of young 5xFAD mice. The 5xFAD 
transgenic mouse was developed by Oakley et al. [22] to 
co-express five familial forms of Alzheimer’s disease [APP 
K670 N/M671L (Swedish) + I716 V (Florida) + V717I 
(London) and PS1 M146L + L286 V]. 5xFAD mice are 
characterised by the early development of Aβ plaques, neu-
roinflammation, neuronal loss, and memory impairment 
[22–24, 30, 31], all hallmarks of human Alzheimer’s dis-
ease. Therefore, these 5xFAD transgenic mice have been 
acknowledged as a useful model for better understanding 
the pathogenesis of human Alzheimer’s disease. In agree-
ment with previous reports [22, 24], we found that first 
signs of amyloidosis and gliosis were detectable in the 
lower cortex and the corpus callosum of 2.5-month-old 
(a)
(b)
(c)
Fig. 3  Aβ staining in wild-type (WT) and 5xFAD mice. a An exam-
ple of an amyloid-β (Aβ) stained section from a 5-month-old (5 mo) 
5xFAD mouse. Area fraction (%) (mean ± SEM) in the lower cor-
tex (b) and corpus callosum (c) were determined in 2.5-month-old 
(2.5 mo) and 5 mo WT and 5xFAD mice. Regions of interest are 
shown by red ellipses. n.s.not significant; ***p < 0.001
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5xFAD mice, although area fractions of GFAP staining 
and Iba-1 staining did not differ significantly from those 
of age-matched controls. However, significant increases 
in both astrocytosis and microgliosis, which occurred in 
parallel to significant increases in the Aβ area fraction, 
were found in the lower cortex, as well as in the corpus 
callosum of 5xFAD mice at the age of 5 months. This is 
the same age at which first behavioural changes, namely 
hippocampus-dependent memory impairments, have been 
observed in 5xFAD mice [22, 31]. Intriguingly, quantifica-
tion of Aβ plaque load in 5-month-old 5xFAD mice com-
pared with levels in 2.5-month-old 5xFAD mice revealed 
only minor increases when compared with the changes 
between 11- and 5-month-old 5xFAD mice. Taken together, 
this suggests that subtle changes in brain Aβ load and/or 
early development of gliosis are sufficient to cause mem-
ory deficits in an Alzheimer’s disease mouse model. Our 
data further point to the importance of Aβ in provoking an 
inflammatory response, since increases in gliosis appear to 
follow after the deposition of Aβ.
MRI T1 relaxation times in young 5xFAD mice
As there is currently urgent need for diagnostic tools capa-
ble of identifying early changes in the brain of patients 
with Alzheimer’s disease, we asked whether MRI T1 
relaxation time can be used (1) to distinguish wild-type 
and 5xFAD mice at an age characterised by early stages 
of Aβ plaque deposition and neuroinflammation and (2) 
to monitor disease progression in young 5xFAD mice. In 
a previous study, we have found that MRI T1 of the lower 
cortex and the corpus callosum were significantly differ-
ent between 11-month-old 5xFAD mice and age-matched 
wild-type controls [25]. Brain tissue T1 is dependent on 
tissue water content [32] and is influenced by a variety of 
factors, which can include myelin density, axonal damage, 
oedema, or widening of extracellular space [33]. However, 
the observed early development of amyloidosis and gliosis 
in young 5xFAD mice was not accompanied by significant 
changes in MRI T1 relaxation time. The T1 differences are 
small between 5-month-old WT and 5xFAD mice, repre-
senting a 6–7% change in the lower cortex and corpus cal-
losum; and there was not a significant difference between 
T1 relaxation times of 2.5- and 5-month-old 5xFAD. In a 
previous study [25] we found T1 reductions confined to 
specific brain regions, for example, the deep layers of the 
cortex; therefore, ROIs must be sized and placed appropri-
ately to be able to capture these changes. Despite focusing 
our attention on the lower cortex and corpus callosum, T1 
values were not significantly different between 5-month-
old 5xFAD and WT mice. Other studies have found no 
T1 differences between AD and WT mice, for example, in 
PS/APP mice 16–23 months old [34], and in ArcAβ mice, 
which have similar T1 values to WT mice irrespective of 
age [35]. It is not known, however, if the lack of T1 change 
in those studies is due to the size and placement of ROIs or 
the use of different AD transgenic models.
We have suggested previously that the presence of 
Aβ plaques may explain differences in MRI T1 between 
11-month-old wild-type and 5xFAD mice [25]. How-
ever, since the beginning of Aβ plaque deposition cannot 
(a)
(b)
(c)
Fig. 4  MRI T1 relaxation times for wild-type (WT) and 5xFAD 
mice. a An example of an MRI T1 quantitative map from a 5-month-
old (5 mo) 5xFAD mouse. MRI T1 (mean ± SEM) were determined 
in the lower cortex (b) and the corpus callosum (c) of WT and 5xFAD 
mice aged 2.5 months (2.5 mo) and 5 mo. Each symbol represents 
data from an individual mouse. Regions of interest are shown by red 
ellipses. No statistics are shown; there was no overall significant dif-
ference between means in the one-way ANOVA, which precludes fur-
ther comparison between means
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be reliably detected by MRI T1, this suggests that only 
substantial Aβ load causes significant changes in MRI T1 
(e.g., in the corpus callosum of 11-month-old mice, WT 
T1 = 1.85 s versus 5xFAD T1 = 1.72 s). This hypothesis is 
supported by our finding that the Aβ area fractions in lower 
cortex and corpus callosum of 11-month-old 5xFAD mice 
were more than 20–30 times larger than those determined 
for the corresponding brain regions in 5-month-old mice. In 
general, reports from other research laboratories of signifi-
cant T1 differences between AD and wild-type mice were 
in old mice when Aβ deposition is fully established [36, 
37]. Thus, an insufficient amount of Aβ in young 5xFAD 
mice could explain the lack of large differences in MRI 
T1 relaxation times between young wild-type and 5xFAD 
mice. We cannot exclude that there might have been T1 
differences in other brain regions of the AD mouse, for 
example, the subiculum [36]; in this work, analysis was 
restricted to the lower cortex and corpus callosum, where 
there are easily identifiable anatomical boundaries that help 
to minimise the subjective nature of ROI placement, and 
where T1 changes in old mice were previously identified 
[25]. Nevertheless, it should be noted that there is still the 
possibility that differences will be found in MRI studies at 
high magnetic field strengths (7.0 T and above) that pro-
vide higher signal-to-noise ratio and improved spatial reso-
lution), with T2 or T2*-weighted imaging, which enables 
the detection of individual Aβ plaques in the mouse [38–
42], ex vivo human [43], and plaque-like pathology in vivo 
human brain [44], and, given the slow rate of Aβ deposi-
tion decades prior to the onset of clinical symptoms in AD 
[2], direct visualisation of plaques as opposed to measur-
ing indirect effects related to Aβ deposition may provide a 
better early diagnostic tool. However, there are unresolved 
questions over the specificity of this technique, and to date, 
most clinical studies use the lower field strength 3 T MRI. 
Further work is needed to develop diagnostic tools capa-
ble of detecting early changes in the brain of AD patients. 
Previous investigations have found magnetisation transfer 
ratio measurements a useful means of assessing changes in 
tissue integrity that may involve gliosis [45–47] (an early 
event in AD); it would be of interest to assess other MRI 
methods such as MTR to give quantitative information on 
the AD mouse brain.
In providing in vivo evaluation of Aβ deposition, PET 
is closer to clinical application than MRI. PET tracers that 
allow direct, in vivo visualisation of Aβ are advancing in 
their development and may allow early detection and moni-
toring of treatment response. Increased Pittsburgh Com-
pound B retention is found in AD patients compared with 
controls [48, 49], and florbetaben, the third amyloid imag-
ing agent to be approved for clinical use (Amyvid [Flor-
betapir F 18] was approved by the FDA in 2012 [50], and 
Vizamyl [Flutemetamol F 18] was approved by the FDA 
in 2013 [51]), demonstrated high sensitivity and specific-
ity for detecting Aβ deposits, and high negative predic-
tive value [52]. That said, large-scale controlled trials are 
needed to assess further the usefulness of these techniques 
in people with early stage AD, who are more likely to bene-
fit from treatment intervention targeting amyloid pathology. 
Furthermore, it is still important to assess other potential 
imaging modalities that may have use within the AD diag-
nostic framework as Aβ-targeted PET is not yet capable of 
diagnosing AD on its own.
The strength of this study is in the quantitative analy-
sis of histological markers Aβ, GFAP, and Iba-1 in young 
5xFAD mice, which takes into account all samples and 
allows a more objective analysis compared with simply 
describing changes seen by the eye. The limitations of this 
study relate to the relatively low MR imaging resolution 
(0.23 × 0.23 × 1 mm). Despite there being no compel-
ling evidence to suggest the mean T1 values differ between 
young 5xFAD and WT mice, we cannot reach a strong con-
clusion; repeated experiments with larger samples would 
be needed; however, given the very small differences in 
T1 between 5-month-old 5xFAD and WT mice this would 
not be recommended based on the results of this study. The 
small size of the mouse brain poses challenges for high-
resolution MR imaging. The use of high field MRI sys-
tems can deliver higher signal-to-noise ratio than what was 
achievable on the 4.7 T system used in this study; we can-
not neglect the impact improved image quality and higher 
imaging resolution would have on improving detection. 
Another important limitation is the discrepancy between 
mouse models and AD brains, which may arise from dif-
ferences in tissue composition and structure, for example, 
Aβ load, tissue-water content, iron accumulation, and loss 
of fibre tracts; therefore, the mouse model does not fully 
recapitulate all the features of AD. For example, impor-
tant differences in the characteristics of plaques in human 
AD and APP/PS1 mice may provide different mechanisms 
of MR contrast changes: plaques in APP/PS1 mice con-
tain less iron, but are more densely packed compared with 
human AD samples [53]. Using voxel-based quantification, 
Su et al. found that AD was characterised by reduced T1 
values in certain brain regions, including bilateral tempo-
ral and parietal lobes in cross-sectional comparison, and an 
increase in T1 in the right caudate, bilateral hippocampus, 
parahippocampus, and thalamus in longitudinal comparison 
[20]. Increased T1 values in white matter of AD patients 
has been reported [54], and taken together this demon-
strates the complex nature of T1 changes in the human AD 
brain. Caution is needed when translating results from ani-
mal to human, and it would be important for future stud-
ies to assess more than one transgenic mouse model. The 
difference between changes in T1 values in mouse mod-
els and human AD may also arise from the relatively low 
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specificity of the measurement. Since brain tissue T1 is 
dependent on a variety of factors, the effect of ongoing dis-
ease on tissue composition may confound using a simple 
T1 relaxation time as a measure of treatment response or 
disease progression.
Conclusion
Our data do not provide sufficient evidence that the mean 
T1 values differ between WT and 5xFAD mice at young 
ages (2.5 and 5 months) despite the transgenic mice having 
pronounced pathology by the age of 5 months compared 
with age-matched WT mice.
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